ホーム › びまん性大細胞型B細胞リンパ腫 › インディアナ州
インディアナ州におけるびまん性大細胞型B細胞リンパ腫の臨床試験
インディアナ州内の拠点で、びまん性大細胞型B細胞リンパ腫に関する9件の研究が参加者を募集しています。
インディアナ州内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Northwest Cancer Center - Crown Point, Crown Point
- Northwest Oncology LLC, Dyer
- Saint Mary Medical Center, Hobart
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- St Vincent Ascension at Peyton Manning Childrens Hospital, Indianapolis
- Investigative Clinical Research of Indiana, Noblesville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- IU Simon Comprehensive Cancer Center, Indianapolis
- Indiana Blood and Marrow Transplantation, Indianapolis
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Indiana Blood and Marrow Transplantation, Indianapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05852717Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- Northwest Cancer Center - Hobart, Hobart
- 他5件
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
被験者募集中第2相
18歳以上 · 全性別 · 2023/04/07更新 · NCT04920617Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Goshen Center for Cancer Care, Goshen
被験者募集中第1/2相
18歳以上 · 全性別 · 2022/08/04更新 · NCT04502394ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。